Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06329492 · ClinicalTrials.gov registry record · Phase 1
Autologous Alpha-2 Macroglobulin Rich Plasma, Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis
A Phase 1 study of Osteoarthritis and Knee Osteoarthritis, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06329492: Completed Phase 1 study of Osteoarthritis and Knee Osteoarthritis, sponsored by Mayo Clinic.
NCT06329492 is a Phase 1 study of Osteoarthritis and Knee Osteoarthritis that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 818-participant average among 135 other Osteoarthritis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06329492, a Phase 1 study of Osteoarthritis and Knee Osteoarthritis, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effectiveness and safety of autologous alpha-2 macroglobulin rich plasma (A2MRP) injections in the treatment of knee osteoarthritis (OA).
Primary Outcome
The number of Adverse Events reported
Conditions Studied
Interventions
- BIOLOGICAL Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP)
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-01-09 |
| Est. Completion | 2026-02-06 |
| Phase | Phase 1 |
What the finished NCT06329492 record still lists
NCT06329492 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 818-participant average among 135 other Osteoarthritis trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Osteoarthritis appearing as the primary indexed condition, and to 1 intervention - of which Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) is the first listed.
NCT06329492 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06329492 about?
NCT06329492 is a clinical study titled "Autologous Alpha-2 Macroglobulin Rich Plasma, Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis". The purpose of this study is to determine the effectiveness and safety of autologous alpha-2 macroglobulin rich plasma (A2MRP) injections in the treatment of knee osteoarthritis (OA).
What is the current status of trial NCT06329492?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-01-09. Estimated completion is 2026-02-06.
What conditions does trial NCT06329492 study?
This clinical trial studies the following conditions: Osteoarthritis, Knee Osteoarthritis, OA.
What interventions are being tested in trial NCT06329492?
The interventions under investigation include: Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06329492?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06329492 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06329492's enrollment target sits among peer trials
20 133rd of 135 higher than 2 of 135 other Osteoarthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sustained Acoustic Medicine for Osteoarthritis Pain
RECRUITING · Phase 1
-
A Study With GLPG1972 in Osteoarthritis Subjects
COMPLETED · Phase 1
-
Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA
COMPLETED · Phase 1
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee
RECRUITING · Phase 2
-
A Prospective, Post-Market, Clinical Follow-up Study of the Incompass™ Total Ankle System
RECRUITING
-
Reliability of Pupil Response to Acute Pain
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI